Funding Tracker/StimCardio Medical
Series A · Cardiovascular · United States
StimCardio Medical raises $30M
Announced October 29, 2026
The round
StimCardio Medical announced a Series A round of $30M on October 29, 2026, led by Metis MedTech. Other participants include Catalyst Health Ventures.
The SignalSupports the planned NeuroPulse 2 pivotal trial and FDA De Novo preparation for Rhyvive. The wearable remains investigational, not FDA cleared or approved. Unnamed strategic and other investors also participated.
What StimCardio Medical does
Investigational wrist-worn neuromodulation designed to complement catheter ablation for atrial fibrillation.
StimCardio Medical is a clinical-stage medical device company developing non-invasive wearable therapeutics for cardiac rhythm disorders. Its investigational Rhyvive device combines physiological sensing with closed-loop median nerve stimulation, with the goal of supporting patients after atrial fibrillation catheter ablation. CEO Amir Soltanianzadeh leads the company. A $30 million Series A announced October 29, 2026, led by Metis MedTech, is expected to fund the planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission. The device is investigational and has not received FDA clearance or approval. Cumulative funding was not disclosed in the announcement. John Slump, CEO and founder of Metis MedTech, and Joshua Phillips, managing partner of Catalyst Health Ventures, are identified as StimCardio board members in the release.
Full StimCardio Medical profile- Company
- StimCardio Medical
- Amount
- $30M
- Stage
- Series A
- Announced
- October 29, 2026
- Led by
- Metis MedTech
- Other investors
- Catalyst Health Ventures
- Vertical
- Cardiovascular
- Country
- United States
- Headquarters
- Los Angeles, California, United States